1. Pink Sheet
  2. >>Legislation

EU Explains New Health Data Space Rules As Framework Becomes ‘A Reality’

 
• By Eliza Slawther

The European Commission has confirmed that pharmaceutical companies will be able to request access to data for research under the new European Health Data Space Regulation, which has been published in the EU Official Journal and will enter into force on 26 March.

The European Health Data Space Regulation will soon enter into force (Shutterstock)
Key Takeaways
  • The European Health Data Space rules will officially enter into force on 26 March following their publication in the Official Journal of the EU on 5 March.
  • The European Commission has released a document answering common questions about the EHDS, which includes key information for pharmaceutical companies and clinical trial sponsors.
  • Industry trade bodies have called for stakeholders to be involved in discussions to implement EHDS.

The much-awaited European Health Data Space (EHDS) framework has become “a reality,” the European Commission’s health directorate (DG SANTE) noted in a social media post to mark the

On the same day, the commission

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

EU Shaping Biotech Act To Unleash SME Potential

 
• By Neena Brizmohun

European companies, in particular small and midsize enterprises, spin-offs and start-ups have a hard time expanding within the single market “because of a complex regulatory framework that is perceived as slow and burdensome,” according to the European Commission.

EU Council Could Adopt Pharma Reform Package Next Week, But Disputes Risk A Year’s Delay

 
• By Eliza Slawther

The Council of the EU wants to adopt its negotiating position on the reform of the general pharmaceutical legislation “sooner, rather than later,” but divergence between member states could push negotiations back another year, a European Commission policy officer said today.

EU HTA Regulation: How Rare Disease Drug Makers Can Meet Worrisome JCAs Data Requirements

 
• By Francesca Bruce

In an interview with the Pink Sheet, Fonadazione Telethon’s Stefano Benvenuti discusses how companies developing and marketing rare disease treatments can overcome the challenges presented by EU-joint clinical assessment evidence requirements.

House Budget Bill Includes Delayed Orphan Fix, Also Risks Downstream Cell and Gene Coverage

 
• By Sarah Karlin-Smith

The first two classes of negotiated drugs under the Inflation Reduction Act would not benefit from a rare disease adjustment House Republicans included in their reconciliation package.

More from Legal & IP